NeoGraph Analytics
Medical DevicesGlobal2026 – 2032

Brain-Computer Interface Market Size, Share & Forecast 2026-2032

BCI estimates spread 9.16x at the base year. A per-trial test against 265 registered studies shows which figures can be clinical revenue, and which cannot.

Revenue, 2026

$795.3M

Forecast, 2032

$2252.5M

CAGR, 2026-2032

18.95%

Report Coverage

Global

Code: brain-computer-interface-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Nine named research houses publish a figure for the brain-computer interface market. They disagree about its present size by a factor of nine. MarketsandMarkets puts 2024 at $262 million; a GII-hosted report puts 2025 at $2.40 billion. Restricting strictly to 2025, Kings Research's $668.8 million against that $2.40 billion is still 3.59x apart. The 2032 endpoints range from $2.25 billion to $9.445 billion, and published growth rates run 9.0% to 18.91%.

In most markets a spread like that signals a scope argument that can be resolved. Here it signals something simpler: there is almost nothing to measure. As of October 2026 no implanted brain-computer interface holds FDA market authorisation -- no premarket approval, no De Novo. Precision Neuroscience cleared one component through 510(k) in May 2025. Neuralink's Blindsight and Synchron's Stentrode hold Breakthrough Device designations, which accelerate review and authorise nothing. Paradromics received an investigational device exemption for a feasibility study in November 2025, and Synchron has said it is preparing its first pivotal trial for approval in 2026. The only commercial approval for an invasive BCI anywhere is China's, for the Neuracle NEO, in March 2026. There is therefore no reimbursed clinical revenue in the United States for any published estimate to be anchored to.

What is countable is the research effort. ClinicalTrials.gov held 265 registered studies matching brain-computer interface on 16 October 2026, 69 of them recruiting, out of 607,160 studies in the register -- 0.044% of all registered clinical research. Divide the published figures by that denominator: MarketsandMarkets' $262 million implies $988,679 per registered study per year, which is the right order of magnitude for research-grade recording hardware, electrode arrays, software and the staff time around them. The $2.40 billion figure implies $9,056,604 per registered study, more than most of these studies' entire budgets, and it cannot be clinical revenue because there is no approved implant to generate any.

So the high estimates are not measuring medicine. They are measuring non-invasive consumer and research neurotechnology -- EEG headsets, attention wearables, software platforms -- under a clinical-sounding title. That distinction, not the forecast, is what a reader should take from this literature.

02

Key Highlights

1

Base-year estimates spread 9.16x, from $262 million for 2024 to $2.40 billion for 2025, across nine named houses

2

No implanted brain-computer interface held FDA market authorisation as of October 2026, so there is no reimbursed clinical revenue to anchor any estimate

3

ClinicalTrials.gov held 265 registered BCI studies on 16 October 2026, 69 recruiting, out of 607,160 -- 0.044% of the register

4

$262 million over 265 studies is $988,679 each, which matches research instrumentation; $2.40 billion is $9,056,604 each, which matches nothing in medicine

5

The global implanted population is in the low hundreds, known only from company statements rather than registries

6

China granted the first commercial approval anywhere for an invasive BCI, the Neuracle NEO, in March 2026, ahead of the FDA

7

Every forecast in this category, including this one, is contingent on a first FDA approval that has not happened

03

Market Overview

Market Context

A brain-computer interface reads neural activity and turns it into a control signal, letting a person operate a computer, a cursor, a communication system or a prosthesis without moving. The clinical case is narrow, serious and entirely uncontroversial: people with tetraplegia, late-stage ALS, brainstem stroke or locked-in syndrome have no other route to communication or control. The commercial case barely exists yet, and the reason is regulatory rather than technical. An implanted BCI is a Class III device and must take the premarket approval route, with clinical evidence of safety and effectiveness for a defined indication. The FDA has issued dedicated leapfrog guidance for implanted brain-computer interface devices for patients with paralysis or amputation, which is a signal of regulatory engagement, not of approval. No company has completed that route. Synchron has said it is preparing its first pivotal trial in 2026, which places a plausible US approval several years out and well inside, rather than before, most of the published forecast horizons. The implanted population reflects this. Neuralink was reported at 21 patients across four countries as of 28 January 2026; Synchron at six patients with twelve months of follow-up; Blackrock Neurotech's implants are described only as used experimentally in dozens of patients. These are company statements relayed through secondary coverage, not registry or peer-reviewed counts, and they should be read as indicative. The order of magnitude is nevertheless clear and it is the key fact about this market: the global implanted population is in the low hundreds, while published estimates of the market's present value run into the billions. Those two facts can only be reconciled if the billions are not about implants.

The brain-computer interface market is $795.3 million in 2026 on the published series with the clearest base and endpoint, projected to $2,252.5 million by 2032 at an 18.95% CAGR. Published base-year estimates spread 9.16x, from $262 million for 2024 to $2.40 billion for 2025, because there is almost nothing to measure: as of October 2026 no implanted brain-computer interface holds FDA market authorisation and there is no reimbursed clinical revenue anywhere in the United States. ClinicalTrials.gov held 265 registered BCI studies on 16 October 2026, 69 recruiting. Dividing the published figures by that denominator shows the high estimates cannot be clinical-device revenue.

Market Stage

Emerging

Adoption Level

Investigational; no approved implant and no reimbursed clinical use in the United States

Key Trends

Base-year estimates spread 9.16x ($262 million for 2024 to $2.40 billion for 2025) and 2032 endpoints spread 4.20x ($2.25 billion to $9.445 billion)No implanted brain-computer interface held FDA market authorisation as of October 2026: no premarket approval and no De NovoClinicalTrials.gov held 265 registered BCI studies on 16 October 2026, 69 of them recruiting, out of 607,160 studies -- 0.044% of the registerMarketsandMarkets' $262 million base implies $988,679 per registered study per year, which matches research instrumentation; the $2.40 billion base implies $9,056,604, which does notThe global implanted population is in the low hundreds: Neuralink reported 21 patients across four countries as of 28 January 2026 and Synchron six patientsChina granted the first commercial approval anywhere for an invasive BCI, the Neuracle NEO, in March 2026 -- ahead of the FDA
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 18.95%

Base Year (2026)

$795.3M

Forecast (2032)

$2252.5M

CAGR (2026-2032)

18.95%

Market size by year, 2026-2032, in USD Million.
YearMarket size ($ Million)
2026Base year$795.30M
2027$945.90M
2028$1125.20M
2029$1338.40M
2030$1592.10M
2031$1893.80M
2032$2252.50M
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The curve shown here is modelled at a constant 18.95% rate. Kings Research publishes $668.8 million for 2025 and $2,252.5 million for 2032 at a stated 18.91%; the 2026 base of $795.3 million is the published 2025 value advanced one year at that published rate, and the 2032 endpoint is Kings Research's own published figure, unmodified. Those two values reconcile at 18.95% over the six-year window. The intermediate years are interpolation, not separately sourced observations. This series was chosen on the grounding test rather than on being a middle value. Its base sits in the range the trial-count arithmetic rules in as research-instrumentation scale, and it is the only series with an explicit 2025 base that does not require the market to already be nine times the lowest published figure. MarketsandMarkets' $262 million for 2024 is arguably the single most defensible number in the whole set -- it implies $988,679 per registered study, which is exactly what this activity looks like -- but it forecasts only to 2029 and cannot carry a 2032 series. The forecast should be read with an unusual degree of caution, and the reason is specific rather than generic. Almost all of the growth in any BCI forecast is contingent on a single event that has not happened: a first FDA approval of an implanted device, followed by a coverage determination. If that arrives before 2030, the implantable segment begins from approximately zero and the published rates will understate it. If it does not, the segment stays investigational and the entire forecast resolves to the growth of non-invasive research and consumer hardware. No published estimate separates those two cases, which is why the 2032 endpoints differ by 4.20x.

05

Market Dynamics

  • An unmet need with no substitute: tetraplegia, late-stage ALS, brainstem stroke and locked-in syndrome leave no other route to communication or device control
  • FDA regulatory engagement, including dedicated leapfrog guidance for implanted brain-computer interface devices for patients with paralysis or amputation
  • Breakthrough Device designations for Neuralink's Blindsight and Synchron's Stentrode, which accelerate review even though they authorise nothing
  • Substantial private capital into a small number of well-capitalised developers, which has funded first-in-human studies well ahead of any revenue
  • China's approval of the Neuracle NEO in March 2026, which creates a competitive and regulatory precedent other jurisdictions must respond to
06

Market Segmentation

By Type

  • Invasive intracortical microelectrode arrays
  • Endovascular stent-mounted electrode arrays
  • Subdural and epidural surface electrode arrays
  • Non-invasive EEG-based systems
  • Functional near-infrared spectroscopy systems

By End User

  • Academic and research institutions
  • Hospitals and neurosurgical centres
  • Rehabilitation centres
  • Medical device and technology developers
  • Consumer and wellness neurotechnology

By Application

  • Communication and cursor control in paralysis
  • Assistive robotics and prosthesis control
  • Stroke and motor rehabilitation
  • Visual prosthesis and sensory restoration
  • Epilepsy monitoring and research
  • Research instrumentation and neuroscience
07

Competitive Landscape

N

Neuralink

United States

Most visible developer; investigational, no market authorisation

Reported 21 implanted patients across the United States, Canada, the United Kingdom and the United Arab Emirates as of 28 January 2026, a figure relayed through secondary coverage of company reporting rather than a registry or peer-reviewed publication. Holds a Breakthrough Device designation for its Blindsight visual prosthesis, which accelerates review but authorises nothing. Private, with no disclosed revenue and no approved product, so no share figure exists.

S

Synchron

United States / Australia

Furthest advanced on the regulatory pathway; investigational

Delivers its Stentrode electrode array endovascularly rather than through a craniotomy, which materially lowers the procedural risk that constrains approval of this class. Holds a Breakthrough Device designation and has stated it is preparing its first pivotal trial for premarket approval in 2026, which confirms that approval has not been granted. Reported six patients with twelve months of follow-up and no safety events, per a secondary source. Private, with no disclosed revenue.

B

Blackrock Neurotech

United States

Longest research track record; investigational

Supplied the intracortical arrays used in much of the academic BCI literature over the past two decades, which makes it the closest thing in this category to an incumbent and the clearest example of why the defensible market figures look like research instrumentation rather than clinical devices. Its implants are described only as having been used experimentally in dozens of patients; no precise count is public and no revenue is disclosed.

P

Precision Neuroscience

United States

Holds the only relevant FDA clearance, for a component

Obtained a 510(k) clearance in May 2025 for a core part of its brain-computer interface technology, using a thin-film surface array placed without penetrating the cortex. A component clearance is not authorisation of a brain-computer interface, and the distinction matters because the clearance is sometimes reported as though it were. Private, with no disclosed revenue.

P

Paradromics

United States

Early feasibility stage; investigational

Received FDA approval of an investigational device exemption in November 2025 for the Connect-One early feasibility study, a high-channel-count intracortical system aimed at communication in severe paralysis. An IDE permits a trial, not a sale. Private, with no disclosed revenue and no share figure.

N

Neuracle

China

Holds the only commercial approval for an invasive BCI anywhere

The NEO system received commercial approval in China in March 2026, reported as the first commercial approval anywhere for an invasive brain-computer interface medical device. This makes China, rather than the United States, the first jurisdiction in which an invasive BCI may be sold, and is the single most consequential regulatory event in the category to date. No revenue or share figure is public.

08

Recent Developments

26
2026Neuracle

The NEO invasive brain-computer interface received commercial approval in China in March 2026, reported as the first commercial approval anywhere in the world for an invasive BCI medical device.

26
2026Neuralink

Reported 21 implanted patients across the United States, Canada, the United Kingdom and the United Arab Emirates as of 28 January 2026. The figure is company-reported and relayed through secondary coverage; it has not been confirmed by a registry or peer-reviewed publication.

25
2025Paradromics

Received FDA approval of an investigational device exemption in November 2025 for the Connect-One early feasibility study of its intracortical brain-computer interface.

25
2025Precision Neuroscience

Received 510(k) clearance in May 2025 for a core component of its brain-computer interface technology -- a component clearance rather than authorisation of a complete brain-computer interface.

09

Regulatory Landscape

FDA premarket approval (PMA) for implanted brain-computer interfaces as Class III devices: as of October 2026 no implanted BCI holds a PMA or a De Novo authorisation, so none may be marketed in the United StatesFDA Investigational Device Exemption (IDE), the only route under which implanted BCIs are currently used in the United States -- as granted to Paradromics for the Connect-One early feasibility study in November 2025FDA Breakthrough Device designation, held by Neuralink's Blindsight and Synchron's Stentrode, which accelerates interaction with the agency and confers no marketing authorisationFDA leapfrog guidance on implanted brain-computer interface devices for patients with paralysis or amputation, which sets out non-binding recommendations for the evidence such a submission would needFDA 510(k) clearance, which has been granted for a Precision Neuroscience component in May 2025 and for the non-implanted IpsiHand upper-extremity rehabilitation system -- the only BCI-based product in routine clinical useChina National Medical Products Administration approval, which granted the Neuracle NEO the first commercial authorisation for an invasive BCI anywhere in March 2026EU Medical Device Regulation (MDR) 2017/745, under which an active implantable neural interface is Class III and requires notified body conformity assessment and post-market clinical follow-up
10

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. This report is a synthesis of a public clinical trials register, documented regulatory actions and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • ClinicalTrials.gov API v2, query.term='brain-computer interface' OR 'brain computer interface', retrieved 16 October 2026: 265 registered studies; the same query filtered to RECRUITING returns 69; the register held 607,160 studies in total
  • FDA leapfrog guidance on implanted brain-computer interface devices for patients with paralysis or amputation, and the documented regulatory position that no implanted BCI held a PMA or De Novo authorisation as of October 2026
  • BioWorld (2025) on Precision Neuroscience's 510(k) clearance for a core component of its brain-computer interface technology, May 2025
  • Paradromics FDA investigational device exemption approval for the Connect-One early feasibility study, November 2025; Synchron's stated preparation of a first pivotal trial for premarket approval in 2026
  • China National Medical Products Administration commercial approval of the Neuracle NEO invasive brain-computer interface, March 2026
  • Neuralink company reporting relayed in secondary coverage: 21 implanted patients across four countries as of 28 January 2026; Synchron six patients with twelve months of follow-up (both company-stated, neither registry-confirmed nor peer-reviewed)
  • Published market estimates from MarketsandMarkets, Kings Research, Market Research Future, Data Bridge Market Research, GII Research, Precedence Research, Acumen Research and Consulting, Vantage Market Research and Emergen Research
  • RAND Forecasting Initiative question 1509 on FDA market approval for a brain-computer interface by 31 December 2030

Validation: Market size is taken from published third-party estimates and attributed to each house by name; no methodology behind those estimates was inspected, and they are presented as published estimates rather than as verified measurements. The grounding test divides published base-year sizes by the 265 brain-computer interface studies registered on ClinicalTrials.gov as retrieved on 16 October 2026: MarketsandMarkets' $262 million for 2024 gives $988,679 per registered study per year, which is the right order of magnitude for research-grade recording hardware, electrode arrays, software and associated staff time, whereas the $2.40 billion figure gives $9,056,604 per registered study, which exceeds most such studies' entire budgets and cannot be clinical revenue because no implanted brain-computer interface held FDA market authorisation as of October 2026. That test establishes that figures above roughly $1 billion are not measuring clinical devices; it does not establish the correct market size and is not offered as an estimate. A secondary division against an implanted population of roughly 250 patients worldwide is recorded in the research notes only as directional corroboration and is deliberately not used here, because those patient counts come from company statements relayed through secondary coverage rather than from a registry or peer-reviewed publication. The 2026 base value is Kings Research's published 2025 figure advanced one year at Kings Research's own published rate, not a separately published observation. Readers should treat every forecast in this category, including this one, as contingent on a first FDA approval of an implanted device that has not occurred.

11

Strategic Takeaways

Treat any BCI figure above roughly $1 billion as a measure of non-invasive research and consumer neurotechnology, not of clinical devices, because no approved implant exists to generate clinical revenue

Use the trial register as your own check

divide the figure you are given by 265 registered studies and ask whether the per-study result is a believable annual research spend

Watch the regulatory calendar, not the technology demonstrations

the whole forecast turns on a first FDA approval and the coverage determination that would follow it

Treat every implanted-patient count in circulation as company-reported and unconfirmed, and treat any vendor share percentage as unsourced, because every developer is private and pre-revenue

Note that the first jurisdiction to permit commercial sale of an invasive BCI was China in March 2026, which makes US-centric market models incomplete from the outset

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.